Merck’s pembrolizumab with berahyaluronidase alfa demonstrates noninferior PK compared to IV Keytruda in pivotal 3475A-D77 trial: Rahway, New Jersey Saturday, March 29, 2025, 10 ...

Good morning, ladies and gentlemen, and welcome to the Humacyte fourth quarter results conference call. (Operator Instructions) As a reminder, this conference call is being recorded. I'll now turn the ...